公开(公告)号：US20200206222A1

公开(公告)日：2020-07-02

申请号：US16717080

申请日：2019-12-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Dominic REYNOLDS ,  Ming-Hong HAO ,  John WANG ,  Sudeep PRAJAPATI ,  Takashi SATOH ,  Anand SELVARAJ

IPC: A61K31/505 ,  A61K31/5377 ,  A61K31/506

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

公开(公告)号：US20160347717A1

公开(公告)日：2016-12-01

申请号：US15167373

申请日：2016-05-27

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark BOCK ,  Ming-Hong HAO ,  Manav KORPAL ,  Vijay Kumar NYAVANANDI ,  Xiaoling PUYANG ,  Susanta SAMAJDAR ,  Peter Gerard SMITH ,  John WANG ,  Guo Zhu ZHENG ,  Ping ZHU

IPC: C07D231/56 ,  C07D401/14 ,  C07D403/06 ,  C07D401/06 ,  C07D403/12 ,  C07D471/14

CPC classification number: C07D231/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D471/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Abstract translation: 本文公开了化合物或其药学上可接受的盐，以及通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来使用该化合物治疗乳腺癌的方法。 乳腺癌可能是ER阳性乳腺癌，和/或需要治疗的受试者可以表达突变型ER-α蛋白。

公开(公告)号：US20210163456A1

公开(公告)日：2021-06-03

申请号：US17045952

申请日：2019-04-08

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Gregg F. KEANEY ,  John WANG ,  Baudouin GERARD ,  Kenzo ARAI ,  Xiang LIU ,  Guo Zhu ZHENG ,  Kazunobu KIRA ,  Lisa A. MARCAURELLE ,  Marta NEVALAINEN ,  Ming-Hong HAO ,  Morgan Welzel O'SHEA ,  Parcharee TIVITMAHAISOON ,  Sudeep PRAJAPATI ,  Touping LUO ,  Nicholas C. GEARHART ,  Jason T. LOWE ,  Yoshihiko KOTAKE ,  Satoshi NAGAO ,  Regina Mikie KANADA SONOBE ,  Masayuki MIYANO ,  Norio MURAI ,  Andrew COOK ,  Shelby ELLERY ,  Atsushi ENDO ,  James PALACINO ,  Dominic REYNOLDS

IPC: C07D407/06 ,  C07D405/14 ,  A61P35/00 ,  C07D313/00 ,  C07D491/107 ,  C07D487/08 ,  C07D487/10 ,  A61K45/06 ,  C07D405/12 ,  C07D417/12 ,  C07D413/12

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

公开(公告)号：US20180141913A1

公开(公告)日：2018-05-24

申请号：US15821367

申请日：2017-11-22

Applicant: EISAI R & D MANAGEMENT CO., LTD.

Inventor： Mark BOCK ,  Ming-Hong HAO ,  Manav KORPAL ,  Vijay Kumar NYAVANANDI ,  Xiaoling PUYANG ,  Susanta SAMAJDAR ,  Peter Gerard SMITH ,  John WANG ,  Guo Zhu ZHENG ,  Ping ZHU ,  Lorna Helen MITCHELL ,  Nicholas LARSEN ,  Nathalie RIOUX ,  Sudeep PRAJAPATI ,  Dominic REYNOLDS ,  Morgan O'SHEA ,  Thiwanka SAMARAKOON

IPC: C07D231/56 ,  C07D401/14 ,  C07D401/10 ,  C07D413/12 ,  C07D413/14 ,  A61P35/00

CPC classification number: C07D231/56 ,  A61P35/00 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US20250092392A1

公开(公告)日：2025-03-20

申请号：US18557876

申请日：2022-04-28

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Vinod VATHIPADIEKAL ,  Branko MITASEV ,  Courtney EASLEY-NEAL ,  Hyeong Wook CHOI ,  Francis G. FANG ,  John WANG ,  Praveen VEMULA ,  Jung Hwa LEE

IPC: C12N15/113

Abstract: Novel antisense oligonucleotides that induce Exon-2 skipping in the CD33 gene during pre-mRNA splicing, and their use in the treatment of a neurodegenerative disease, such as Alzheimer's disease, are disclosed.

公开(公告)号：US20240368140A1

公开(公告)日：2024-11-07

申请号：US18582548

申请日：2024-02-20

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Gregg F. KEANEY ,  John WANG ,  Baudouin GERARD ,  Kenzo ARAI ,  Xiang LIU ,  Guo Zhu ZHENG ,  Kazunobu KIRA ,  Lisa A. MARCAURELLE ,  Marta NEVALAINEN ,  Ming-Hong HAO ,  Morgan Welzel O'SHEA ,  Parcharee TIVITMAHAISOON ,  Sudeep PRAJAPATI ,  Tuoping LUO ,  Nicholas C. GEARHART ,  Jason T. LOWE ,  Yoshihiko KOTAKE ,  Satoshi NAGAO ,  Regina Mikie KANADA SONOBE ,  Masayuki MIYANO ,  Norio MURAI ,  Andrew COOK ,  Shelby ELLERY ,  Atsushi ENDO ,  James PALACINO ,  Dominic REYNOLDS

IPC: C07D407/06 ,  A61K45/06 ,  A61P35/00 ,  C07D313/00 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

公开(公告)号：US20180127378A1

公开(公告)日：2018-05-10

申请号：US15713107

申请日：2017-09-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark BOCK ,  Ming-Hong HAO ,  Manav KORPAL ,  Vijay Kumar NYAVANANDI ,  Xiaoling PUYANG ,  Susanta SAMAJDAR ,  Peter Gerard SMITH ,  John WANG ,  Guo Zhu ZHENG ,  Ping ZHU

IPC: C07D231/56 ,  C07D401/14 ,  C07D403/12 ,  C07D403/06 ,  C07D471/14 ,  C07D401/06

CPC classification number: C07D231/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D471/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US20170360785A1

公开(公告)日：2017-12-21

申请号：US15627851

申请日：2017-06-20

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic REYNOLDS ,  Ming-Hong HAO ,  John WANG ,  Sudeep PRAJAPATI ,  Takashi SATOH ,  Anand SELVARAJ

IPC: A61K31/505 ,  C07D405/12 ,  C07D403/12 ,  C07D401/12 ,  C07D239/48 ,  C07C53/18 ,  A61K31/5377 ,  C07D413/12 ,  A61K31/506

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

公开(公告)号：US20170007601A1

公开(公告)日：2017-01-12

申请号：US15221018

申请日：2016-07-27

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic REYNOLDS ,  Ming-Hong HAO ,  John WANG ,  Sudeep PRAJAPATI ,  Takashi SATOH ,  Anand SELVARAJ

IPC: A61K31/505 ,  A61K31/5377 ,  G01N33/574 ,  A61K31/506

CPC classification number: A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  C07C53/18 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Abstract translation: 本文提供了可用作FGFR4抑制剂的式I化合物，以及其用途的方法。